Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2.

Trial Profile

Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2014

At a glance

  • Drugs Aliskiren (Primary) ; Angiotensin receptor antagonists
  • Indications Essential hypertension
  • Focus Pharmacodynamics
  • Acronyms SMART-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Feb 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 03 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top